Translated title of the contribution | Persistent OCS Reduction Regardless of Starting OCS Dose in Patients With Severe, OCSDependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study |
---|---|
Original language | Spanish |
Publication status | Accepted/In press - 2 Mar 2022 |
Event | 55 Congreso Separ - Pamplona, Spain Duration: 2 Jun 2022 → 4 Jun 2022 Conference number: 55th https://www.congresosepar.com/SEPAR2022 |
Conference
Conference | 55 Congreso Separ |
---|---|
Country/Territory | Spain |
City | Pamplona |
Period | 2/06/22 → 4/06/22 |
Internet address |
Bibliographical note
It will be published in English and Spanish.Acknowledgments and funding sources
Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Éilis Sutton, PhD, of Excerpta Medica, and was funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.